UPDATED: Pfizer's Prevenar 13 patent challenged in India as MSF continues its price fight
The medical charity Médecins Sans Frontières is taking its fight with Pfizer over the cost of top selling vaccine Prevenar 13 to a new level. It is challenging the drugmaker's request for a patent on the vax in India.
All of the shots--minus Gardasil--showed signs of slowing, with the sharpest CAGR drop of 4% in Prevnar's case. Gardasil, last year expected to grow just 2%, is in this year's report estimated to post 4% growth through 2020.
From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 4)
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
Pfizer said on Thursday that it would be pulling its vaccines sales business out of China after the import license of Prevenar, its top-selling treatment, was not renewed, Reuters reported.
Prevnar pneumonia jabs have been wildly successful for Pfizer, racking up billions of dollars in sales and almost single-handedly driving its vaccine business.
Pfizer's vaccine hope Prevenar 13 wins new EU nod in adults
One reason Pfizer snapped up Wyeth in 2009: Its Prevnar/Prevenar vaccine franchise. Now, the latest version of the pneumococcal shot is Pfizer's fourth-biggest seller, with $3.72 billion in 2012 revenues. But Pfizer wants even more.
In pandemic flu preparation, a lot of focus is placed on protecting against the specific viral strain. Yet analysis of the 1918 pandemic shows secondary bacterial pneumonia directly caused many of the deaths. This brings Pfizer's Prevnar 13 into play, and the Big Pharma is talking up its role.
Pfizer sales drop 16%, falling short of expectations
Once again, Lipitor's patent loss gave Pfizer's ($PFE) quarterly results a big wallop. The cholesterol fighter's sales plummeted by 71% year over year, to $749 million. That drop, if a bit bigger than anticipated, was expected; it's been expected for years. So, the company's 16% drop in sales, to about $14 billion, is no wake-up call.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. Take a look at the full list >>